ALESSIA BUROCCHI ET AL: "Intratumor OX40 stimulation inhibits IRF1 expression and IL-10 production by Treg cells while enhancing CD40L expression by effector memory T cells", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 41, no. 12, 10 December 2011 (2011-12-10), pages 3615-3626, XP055229585, DE ISSN: 0014-2980, DOI: 10.1002/eji.201141700 (B1)

AMY E MORAN ET AL: "The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy", CURRENT OPINION IN IMMUNOLOGY, vol. 25, no. 2, 1 April 2013 (2013-04-01), pages 230-237, XP055149673, ISSN: 0952-7915, DOI: 10.1016/j.coi.2013.01.004 (B1)

CHONAN MASASHI ET AL: "CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models", NEURO-ONCOLOGY : OFFICIAL JOURNAL OF THE WORLD FEDERATION OF NEURO-ONCOLOGY, OXFORD : OXFORD UNIV. PRESS, GB, vol. 17, no. 11, 24 May 2015 (2015-05-24), pages 1453-1462, XP009187309, ISSN: 1523-5866 (B1)

David Bajor: "Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma", , 22 April 2015 (2015-04-22), XP055229369, Retrieved from the Internet: URL:http://cancerres.aacrjournals.org/cont ent/75/15_Supplement/CT137.short?rss=1 [retrieved on 2015-11-18] (B1)

L. C. SANDIN ET AL: "Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 1, 1 January 2014 (2014-01-01) , pages 80-90, XP055218221, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-13-0067 (B1)

M. GERLONI ET AL: "Functional cooperation between T helper cell determinants", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 97, no. 24, 21 November 2000 (2000-11-21), pages 13269-13274, XP055229725, US ISSN: 0027-8424, DOI: 10.1073/pnas.230429197 (B1)

WO-A2-2008/051424 (B1)

SARA M MANGSBO ET AL: "ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), page P42, XP021167252, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P42 (B1)

SORENSEN M R ET AL: "Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 41, 24 September 2010 (2010-09-24), pages 6757-6764, XP027267149, ISSN: 0264-410X [retrieved on 2010-08-02] (B1)

TOMOYASU UNO ET AL: "Eradication of established tumors in mice by a combination antibody-based therapy", NATURE MEDICINE, vol. 12, no. 6, 7 May 2006 (2006-05-07), pages 693-698, XP055123624, ISSN: 1078-8956, DOI: 10.1038/nm1405 (B1)

WO-A1-2010/024676 (B1)

WO-A1-2013/034904 (B1)

WO-A1-2014/121099 (B1)

R. H. VONDERHEIDE ET AL: "Agonistic CD40 Antibodies and Cancer Therapy", CLINICAL CANCER RESEARCH, vol. 19, no. 5, 1 March 2013 (2013-03-01), pages 1035-1043, XP055218372, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-12-2064 (B1)